Targeted drug shows promise for Hard-to-Treat lung cancer
Disease control
Terminated
This study tested a drug called poziotinib in 648 people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 mutations). The goal was to see if the drug could shrink tumors. The study was stopped early, but results showed some patients…
Phase: PHASE2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC